Prevalence of diabetic retinopathy & sight threatening diabetic retinopathy in Hong Kong.

Are we more or less at risk?



Dr. Rita Gangwani









Introduction

 Diabetic retinopathy (DR): a leading cause of blindness in working age individuals

 Advanced and irreversible DR may be asymptomatic



- Timely detection is essential to prevent blindness
- Timely laser treatment can preserve vision in subjects with sight threatening DR (STDR)




Visual acuity is misleading...



VA = 6/9






VA = 6/12



Objective

- ➤ To detect prevalence of DR and STDR in
- Hong Kong (HK) as a whole &
- in different clusters in HK and
- to compare with the global prevalence rate of DR






Methods

- Screening at primary care outpatient clinics under the 'Risk Assessment and Management Programme (RAMP)'
- > Examination of :
 - visual acuity,
 - anterior segment examination,
 - dilatation of pupils,
 - digital retinal fundus photography by trained optometrists.


The Screening process




Grading of fundus photo for +/- and severity of DR

Grading Protocol

- Image Quality
- Artifacts
- Severity of the disease
- Other eye diseases
- Arbitration
- Quality Assurance





Methods....contd..

Systematic grading of fundus photographs for grades of DR according to the English national screening programme.

Primary grading (by optometrist)

Secondary grading (by optometrist)

Arbitration grading (by ophthalmologist)

GRADES OF DR:

- No DR
- Background/ Non- proliferative DR
- Pre-proliferative DR
- Proliferative DR
- Maculopathy

STDR (sight threatening DR)

Diabetic Retinopathy Grading Standard Grading International Term Action **Features Annual screening** R0No diabetic retinopathy Normal retina Mild non-proliferative Hemorrhages and micro aneurysms only **R**1 **Annual screening** diabetic retinopathy R2 Moderate non-Extensive micro aneurysms (MAs), intraretinal hemorrhages, Appt within 13 proliferative diabetic and hard exudates weeks retinopathy R2 Severe non-Venous abnormalities, large blot hemorrhages, cotton wool Appt within 13 proliferative diabetic spots (small infarcts), venous beading, venous loop, venous weeks reduplication, and IRMA retinopathy Proliferative diabetic **R3** New vessel formation either at the disc (NVD) or elsewhere Appt within 2 (NVE). weeks retinopathy Pre-retinal fibrosis ± **R3** Extensive fibro vascular proliferation, retinal detachment, pre-Appt within 2 tractional retinal retinal or vitreous hemorrhage, glaucoma and subhyaloid weeks detachment hemorrhage M₀ No maculopathy No maculopathy **Annual screening** M1 Exudative: leakage, retinal thickening, MAs, HEs Maculopathy Appt within 13 Ischemic: featureless macula with NVE and poor VA weeks Milder forms: •exudate ≤1DD of centre of fovea •circinate or group of exudates within macula •any MAs or hemorrhage ≤1DD of centre of fovea only if associated with a best VA of $\leq 6/12$ •retinal thickening ≤1DD of centre of fovea P Photocoagulation Small retinal scars through out the peripheral retina. Appt < 2 weeks IJ Un-gradable Ungradable: cataract or other lesions -referred for assessment Appt < 4 weeks

International Council of Ophthalmology Diabetic Retinopathy grading (2014)

Diabetic Retinopathy	Findings Observable on dilated ophthalmoscopy	Referral
No apparent retinopathy	No abnormalities	Review in 1-2 years
Mild nonproliferative DR	Microaneurysms only	Review in 1-2 years
Moderate nonproliferative	More than just microaneurysms,	Review in 6 months -1 year; or
DR	but less	refer
	than severe nonproliferative DR	to ophthalmologist
Severe nonproliferative	Any of the following:	Refer to ophthalmologist
DR	 Intraretinal hemorrhages 	
	(≥20 in each quadrant);	
	Definite venous beading (in 2	
	quadrants);	
	 Intraretinal microvascular 	
	abnormalities (in 1 quadrant)	
	and no signs of proliferative	
	retinopathy	
Proliferative DR	Severe nonproliferative DR and	Refer to ophthalmologist
	1 or more of	
	the following:	
	 Neovascularization 	
	Vitreous/preretinal	
	hemorrhage	

Results

Total No of subjects screened:
N= 145888
(Nov 2009-Aug 2013)

Ungradable photos: N= 8151 (5.6%)

Prevalence of DR (any DR) = 40.1% (95% CI: 39.9-40.4)

Prevalence of DR (different clusters) = 33.4%-49.8%


Prevalence of STDR = **10.2%** (95% CI: 10.0-10.3)

Prevalence of STDR (different clusters) = 7.3%-11.9%

Prevalence of maculopathy = 8.9% (95% CI: 8.8-9.0)

Prevalence of maculopathy (different clusters) = 8.0%-10.1%

Results



Are we more or less at risk?

Prevalence	Hong Kong % (95% CI)	Global prevalence [1]
Any DR	40% (39.9-40.4)	34.6%(34.5-34.8)
STDR/VTDR	10.2% (10.0-10.3)	10.2%(10.1-10.3)
Maculopathy	8.9% (8.8-9.0)	6.81% (6.74-6.89)
PDR	0.3% (0.20-0.38)	6.96%(6.87-7.04)

[1] Yau JW,Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012;35(3):556-64.

Are we more or less at risk?

Prevalence	Hong Kong % (95% CI)	Global prevalence [1]
Any DR	40% (39.9-40.4)	34.6%(34.5-34.8) Caucasian: 45.8% African-American: 49.6% Hispanic: 34.6% Chinese:25.1% Asian: 19.9%
STDR/VTDR	10.2% (10.0-10.3)	10.2%(10.1-10.3)
Maculopathy	8.9% (8.8-9.0)	6.81% (6.74-6.89)
PDR	0.3% (0.20-0.38)	6.96%(6.87-7.04)

Conclusions

- The overall prevalence of DR in Hong Kong was 40%
- The prevalence of STDR was 10.2%.
- The prevalence of maculopathy was slightly higher than global prevalence (7.5%)- Screening methodology
- The prevalence of proliferative DR was < 1.0% in our population as compared to the global prevalence of 7.0%
- There was little variation in DR or STDR between clusters.

Conclusion...

- The screening programme under 'RAMP' was more objective method to assess DR truly worthwhile
- An integral system with 'Arbitration and Quality assurance'
- Traceable and with an ability to detect progression on subsequent screening episodes
- This could not have been achieved without RAMP other than direct ophthalmoscopy
- Screening and grading <u>less labor intensive</u> than examining with direct ophthalmoscopy

Ackowledgement

- Prof. David Wong¹
- Prof. Sarah McGhee²
- Prof. Cindy L K Lam³
- Prof. Jimmy Lai¹

Dept of Ophthalmology, The University of Hong Kong School of Public Health, The University of Hong Kong Dept of Family Medicine and Primary Care, The University of Hong Kong



Acknowledgement

- Screening staff:
 All the optometrists in DR Screening programme
- All doctors and staff of the RAMP and in secondary care hospitals
- Our IT support team:
 Mr. Ray C.M. Wong
- Statistical help:
 - -Christina Chan
 - -Tina Lian
 - -Catherine Chan

Thank you